PRESS RELEASES

• For the first time, a tumor microenvironment immune gene signature associated with CAR T-cell treatment of non-Hodgkin...

• Immune gene expression signature Immmunosign® was applied to a set of pre and post LTX-315 treatment biopsies
• Immunosign®...

• Immunoscore® Colon is strongly prognostic in the N0147 600 patient cohorts

• Using pre-specified cut off in a...

• Immunoscore® Colon strong prognostic performance confirmed on N0147 patients’ samples and presented in poster sessions...

• HalioDx has successfully performed critical development phases for Ipsogen® JAK2 510(k) in close collaboration with...

• Immunoscore® Colon is the first standardized immune‐based assay for the classification of cancers

• Immunoscore® has...

• Analyzing both adaptive immunity (CD8+ T cells) and PD-L1 expression status should allow clinicians to improve Immune...

HalioDx sees strong development of its clinical research activity toward precision immunotherapy

Dr. Jérôme GALON presented today positive results from the Immunoscore® study, an international initiative led by the...

HalioDx, a novel company that designs and develops a new class of immune oncology scoring tests for cancer diagnostics,...

Dr. Jérôme Galon to present results of the Immunoscore® worldwide SITC(1) study during the Gastrointestinal Cancer Oral...

HalioDx SAS, a diagnostic company in immuno-oncology, and NanoString Technologies, Inc, a provider of life science tools...

Marseille - France, February 16, 2016

In the January 2016 issue of OncoImmunology, the study by Berghoff et al....

HalioDx ‘s team is attending this fall the most prestigious scientific meetings in the field of Oncology and...